Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,248 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo group Clear all
Completed Phase 2 Interventional

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT02136940
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 2 Interventional

Pilot Study in Patients With Symptomatic Steroid-Naive Asthma

NCT00024544
View directory record Official record
Conditions
Asthma
Interventions
anti-IL-4 monoclonal antibody (pascolizumab)
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
18
States / cities
Los Angeles, California • Mission Viejo, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 12, 2026, 6:35 PM EDT
Active, not recruiting Phase 2 Interventional Results available

RCT of CBD for Anxiety in Advanced Breast Cancer

NCT04482244
View directory record Official record
Conditions
Advanced Breast Cancer, Anxiety, CBD
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Goals for Reaching Optimal Wellness: GROWell

NCT04449432
View directory record Official record
Conditions
Pregnancy Related, Gestational Weight Gain, Postpartum Weight Retention, Overweight and Obesity
Interventions
GROWell (Interactive Obesity Treatment Approach), Attention Support Control
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 12, 2026, 6:35 PM EDT
Recruiting Phase 3 Interventional

Stress Hydrocortisone In Pediatric Septic Shock

NCT03401398
View directory record Official record
Conditions
Septic Shock
Interventions
Hydrocortisone, sodium succinate, Normal saline
Drug
Lead sponsor
Jerry Zimmerman
Other
Eligibility
1 Month to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Massage on the Immune System of Preterm Infants

NCT00317278
View directory record Official record
Conditions
Premature Birth, Stress
Interventions
massage therapy, Sham
Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
28 Weeks to 33 Weeks
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

NCT00154063
View directory record Official record
Conditions
Migraine Prophylaxis
Interventions
E2007, Placebo
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 12, 2026, 6:35 PM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 12, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06252285
View directory record Official record
Conditions
RSV Immunisation
Interventions
RSVt Vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
6,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Placebo, Dapirolizumab pegol (DZP)
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

NCT03395184
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
57
States / cities
Dothan, Alabama • Beverly Hills, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00542425
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide, Placebo, BA058 20 µg, BA058 40 µg, BA058 80 µg
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 1Phase 2 Interventional

Zofin to Treat COVID-19 Long Haulers

NCT05228899
View directory record Official record
Conditions
COVID-19
Interventions
Zofin, Placebo
Drug · Other
Lead sponsor
ZEO ScientifiX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Newport Beach, California • North Hollywood, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency

NCT01700387
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA, Topiramate, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 12, 2026, 6:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

NCT00404014
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
AL-208, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
50 Years to 79 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Laguna Hills, California • Sacramento, California • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 12, 2026, 6:35 PM EDT
Terminated Phase 3 Interventional Results available

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

NCT01975389
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
bococizumab (PF-04950615), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10,564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
518
States / cities
Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Oct 12, 2026, 6:35 PM EDT
Terminated Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant low dose, Deucrictibant high dose, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Protandim Supplementation on Oxidative Damage and Athletic Performance

NCT02172625
View directory record Official record
Conditions
Oxidative Stress
Interventions
Protandim Dietary Supplement, Placebo Group
Dietary Supplement · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 12, 2026, 6:35 PM EDT
Active, not recruiting Phase 3 Interventional

LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

NCT05983250
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 12, 2026, 6:35 PM EDT
Completed Phase 1 Interventional

Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia

NCT00002148
View directory record Official record
Conditions
Cognitive Disorders, HIV Infections
Interventions
OPC 14117
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 12, 2026, 6:35 PM EDT